Research progress of selenium preparation in the treatment of thyroid associated ophthalmopathy

doi:10.3877/cma.j.issn.2095-2007.2022.05.011

Abstract

Abstract:

Thyroid associated ophthalmopathy (TAO) is an organ specific autoimmune disease related to autoimmune thyroid disease, which ranks first in adult orbital disease. Selenium is an essential biological trace element in human body, which maintains the body function through the action of selenium protein. It has demonstrated that selenium has a certain effect on mild active TAO. At the same time, the European Graves′ ophthalmopathy collaborative group on Graves orbitopathy clinical practice guidlines recommend that the early mild TAO patients should be treated with selenium, which can improve the eye symptoms, the quality of life and prevent the disease from escalating. However, its mechanism is still unclear. Based on these, the treatment mechanism, application and its prospect of selenium preparation in TAO were reviewed.

Key words: Thyroid associated ophthalmopathy, Selenium, Selenoprotein, Oxidative stress

Peng Zhang, Zhaoxia Zhang, Chunfang Yan, Bin Sun. Research progress of selenium preparation in the treatment of thyroid associated ophthalmopathy[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2022, 12(05): 316-320.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2022.05.011

https://zhykyxzz.cma-cmc.com.cn/EN/Y2022/V12/I05/316

Figures/Tables 1

References 55

[1]	邵毅，陈偲翊，廖许琳. 2019甲状腺相关性眼病管理实用指南解读[J]. 国际眼科杂志，2021，21(8):1408-1411.
[2]	Kieliszek M. Selenium fascinating microelement, properties and sources in food[J]. Molecules, 2019, 24(7): 1318-1322.
[3]	Gontarz－Nowak K, Szychlińska M, Matuszewski W, et al. Current knowledge on Graves′ orbitopathy[J]. J Clin Med, 2020, 10(1): 30-32.
[4]	姬璇，张朝霞，闫春芳，等. 甲状腺相关性眼病氧化应激反应的研究进展[J/OL]. 中华眼科医学杂志(电子版)，2021，11(2):124-128.
[5]	Nessel TA, Gupta V. Selenium[M]. Treasure Island (FL) : StatPearls, 2021.
[6]	Lumyongsatien M, Bhaktikamala U, Thongtong P, et al. Relative selenium insufficiency is a risk factor for developing severe Graves′ orbitopathy: a case－control study[J]. BMJ Open Ophthalmol, 2021, 6(1): e000713.
[7]	Labunskyy VM, Hatfield DL, Gladyshev VN. Selenoproteins: molecular pathways and physiological roles[J]. Physiol Rev, 2014, 94(3): 739-777.
[8]	Bianco AC, Salvatore D, Gereben B, et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases[J]. Endocr Rev, 2002, 23(1): 38-89.
[9]	易春峰，李元红. 硒预防心血管病的研究进展[J]. 中国老年学杂志，2015，35(12):3470-3471.
[10]	Wu Q, Rayman MP, Lv H, et al. Low Population Selenium Status Is Associated With Increased Prevalence of Thyroid Disease[J]. J Clin Endocrinol Metab, 2015, 100(11): 4037-4047.
[11]	Bülow PI, Knudsen N, Carlé A, et al. Serum selenium is low in newly diagnosed Graves′ disease: a population－based study[J]. Clin Endocrinol (Oxf), 2013, 79(4): 584-590.
[12]	Wertenbruch T, Willenberg HS, Sagert C, et al. Serum selenium levels in patients with remission and relapse of graves′ disease[J]. J Med Chem, 2007, 3(3): 281-284.
[13]	Arikan TA. Plasma selenium levels in first trimester pregnant women with hyperthyroidism and the relationship with thyroid hormone status[J]. Biol Trace Elem Res, 2015, 167(2): 194-199.
[14]	Wang W, Mao J, Zhao J, et al. Decreased thyroid peroxidase antibody titer in response to selenium supplementation in autoimmune thyroiditis and the influence of a selenoprotein P gene polymorphism: a prospective, multicenter study in China[J]. Thyroid, 2018, 28(12): 1674-1681.
[15]	Qiu Y, Xing Z, Xiang Q, et al. Insufficient evidence to support the clinical efficacy of selenium supplementation for patients with chronic autoimmune thyroiditis[J]. Endocrine, 2021, 73(2): 384-397.
[16]	Winther KH, Rayman MP, Bonnema SJ, et al. Selenium in thyroid disorders——Essential knowledge for clinicians[J]. Nat Rev Endocrinol, 2020, 16(3): 165-176.
[17]	Khong JJ, Goldstein RF, Sanders KM, et al. Serum selenium status in Graves′ disease with and without orbitopathy: a case－control study[J]. Clin Endocrinol, 2014, 80(6): 905-910.
[18]	Duntas LH, Benvenga S. Selenium: an element for life[J]. Endocrine, 2015, 48(3): 756-775.
[19]	Marinò M, Menconi F, Dottore GR, et al. Selenium in Graves hyperthyroidism and orbitopathy[J]. Ophthalmic Plast Reconstr Surg, 2018, 34(4S1): S105-S110.
[20]	Shreenath AP, Ameer MA, Dooley J. Selenium deficiency[M]. Treasure Island (FL) : StatPearls, 2021.
[21]	Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves′ orbitopathy[J]. N Engl J Med, 2011, 364(20): 1920-1931.
[22]	Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves′ Orbitopathy Guidelines for the Management of Graves′ Orbitopathy[J]. Eur Thyroid J, 2016, 5(1): 9-26.
[23]	朴司晨. 硒干预轻、中度Graves眼病的安慰剂对照临床研究[D]. 北京：中国医科大学，2017.
[24]	肖新怀，陈澍，苏丽芳. 硒辅助治疗Graves病伴轻度突眼的临床疗效[J]. 中国现代医学杂志，2017，27(11):91-94.
[25]	张祎，张险峰，韩辉，等. 中小剂量甲泼尼龙联合甲氨蝶呤与硒酵母对Graves眼病的疗效观察[J]. 中华内分泌代谢杂志，2016，25(1):24-26.
[26]	柴佩韦. 硒补充疗法对甲状腺相关眼病治疗机制的研究进展[J]. 中华实验眼科杂志，2017，35(9):857-861.
[27]	Marinò M, Dottore GR, Leo M, et al. Mechanistic pathways of selenium in the treatment of Graves′ disease and Graves′ orbitopathy[J]. Horm Metab Res, 2018, 50(12): 887-893.
[28]	Lanzolla G, Marcocci C, Marinò M. Antioxidant therapy in Graves′ orbitopathy[J]. Front Endocrinol (Lausanne), 2020, 11: 608733.
[29]	Lanzolla G, Marinò M, Marcocci C. Selenium in the treatment of Graves′ hyperthyroidism and eye disease[J]. Front Endocrinol (Lausanne), 2020, 11: 608428.
[30]	Kieliszek M, Baejak S. Current knowledge on the importance of selenium in food for living organisms: a review[J]. Molecules (Basel, Switzerland), 2016, 21(5): 451-456.
[31]	ZarkoviĉM. The role of oxidative stress on the pathogenesis of graves′ disease[J]. J Thyroid Res, 2012: 302537.
[32]	Hasani M, Djalalinia S, Khazdooz M, et al. Effect of selenium supplementation on antioxidant markers: a systematic review and meta－analysis of randomized controlled trials[J]. Hormones (Athens), 2019, 18(4): 451-462.
[33]	Fernández－Lázaro D, Fernandez－Lazaro CI, Mielgo－Ayuso J, et al. The role of selenium mineral trace element in exercise: antioxidant defense system, muscle performance, hormone response, and athletic performance: a systematic review[J]. Nutrients, 2020, 12(6): 1790.
[34]	Huang Z, Rose AH, Hoffmann PR. The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities[J]. Antioxid Redox Signal, 2012, 16(7): 705-743.
[35]	Rotondo DG, Leo M, Casini G, et al. Antioxidant actions of selenium in orbital fibroblasts: a basis for the effects of selenium in Graves′ orbitopathy[J]. Thyroid, 2017, 27(2): 271-278.
[36]	张方华，阎胜利，余霄龙，等. 亚硒酸钠对体外培养人甲状腺细胞氧化损伤的影响[J]. 免疫学杂志，2008，24(2):139-141.
[37]	Tamura T, Stadtman TC. A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity[J]. Proc Natl Acad Sci U S A, 1996, 93(3): 1006-1011.
[38]	张辉，刘明法，李少臣，等. 硒和蛋白质对大鼠心肌形态结构及谷胱甘肽过氧化物酶和线粒体型硫氧还蛋白还原酶表达的影响[J]. 中国地方病学杂志，2012，31(1):40-45.
[39]	何志伟，胡欣，陈国芳，等. 甲状腺相关性眼病病因、发病机制及免疫靶向治疗的研究进展[J]. 山东医药，2020，60(28):90-93.
[40]	Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid－associated ophthalmopathy[J]. Invest Ophth Vis Sci, 2014, 55(3): 1735-1748.
[41]	Bahn RS. Current insights into the pathogenesis of Graves′ ophthalmopathy[J]. Horm Metab Res, 2015, 47(10): 773-778.
[42]	Lantz M, Planck T, Asman P, et al. Increased TRAb and/or low anti－TPO titers at diagnosis of graves′ disease are associated with an increased risk of developing ophthalmopathy after onset[J]. Exp Clin Endocrinol Diabetes, 2014, 122(2): 113-117.
[43]	Xu B, Wu D, Ying H, et al. A pilot study on the beneficial effects of additional selenium supplementation to methimazole for treating patients with Graves′ disease[J]. Turk J Med Sci, 2019, 49(3): 715-722.
[44]	Wichman J, Winther KH, Bonnema SJ, et al. Selenium Supplementation significantly reduces thyroid autoantibody levels in patients with chronic autoimmune thyroiditis: a systematic review and meta－analysis[J]. Thyroid, 2016, 26(12): 1681-1692.
[45]	Hai YP, Lee ACH, Frommer L, et al. Immunohistochemical analysis of human orbital tissue in Graves′ orbitopathy[J]. J Endocrinol Invest, 2020, 43(2): 123-137.
[46]	Balázs C, Kaczur V. Effect of selenium on HLA－DR EXPRESSION OF Thyrocytes[J]. Autoimmune Dis, 2012: 374635.
[47]	Shrimali RK, Irons RD, Carlson BA, et al. Selenoproteins mediate T cell immunity through an antioxidant mechanism[J]. J Biol Chem, 2008, 283(29): 20181-20185.
[48]	Tinkov AA, Ajsuvakova OP, Filippini T, et al. Selenium and selenoproteins in adipose tissue physiology and obesity[J]. Biomolecules, 2020, 10(4): 658.
[49]	Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves′ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves′ orbitopathy[J]. Eur J Endocrinol, 2021, 185(4): G43-G67.
[50]	中国营养学会. 最新中国居民膳食营养素参考摄入量要点精编[J]. 健康指南：中老年，2016，28(11):32-33.
[51]	Rayman MP. Selenium and human health[J]. Lancet, 2012, 379(9822): 1256-1268.
[52]	乔晶. Graves眼病患者血清外泌体miRNA表达谱的差异性分析及硒干预对其远期预后影响的前瞻队列研究[D]. 北京：中国医科大学，2021.
[53]	王英爽，王雅文，张新玮. 眼眶减压术联合硒酵母片治疗对Graves伴突眼症患者疗效及对TSH、HA水平的影响[J]. 湖南师范大学学报(医学版)，2020，7(1):158-161.
[54]	李丹丹，刘扬，元荣荣，等. 硒酵母联合甲巯咪唑治疗Graves病伴轻度突眼的临床效果[J]. 河南医学研究，2020，29(2):217-220.
[55]	Almanza－Monterrubio M, Garnica－Hayashi L, Dávila－Camargo A, et al. Oral selenium improved the disease activity in patients with mild Graves′ orbitopathy[J]. J Fr Ophtalmol, 2021, 44(5): 643-651.

Please choose a citation manager

Content to export